Pralsetinib Market Introduction
Pralsetinib, market under the brand name Gavreto, has emerged as a promising treatment option for patients with specific types of cancer harboring RET gene alterations. This targeted therapy has demonstrated significant efficacy in treating metastatic non-small cell lung cancer (NSCLC) and advanced RET fusion-positive thyroid cancer.
Unlock your exclusive...
English
Arabic
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian